Related references
Note: Only part of the references are listed.Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model
Christina H. Wang et al.
CANCER RESEARCH (2009)
SAFETY AND EFFICACY OF BEVACIZUMAB WITH HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR RECURRENT MALIGNANT GLIOMAS
Philip H. Gutin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Experience with irinotecan for the treatment of malignant glioma
James J. Vredenburgh et al.
NEURO-ONCOLOGY (2009)
Safety and Efficacy of Adjunctive Balloon Remodeling during Endovascular Treatment of Intracranial Aneurysms: A Literature Review
M. Shapiro et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2008)
18F-FDG PET of common enhancing malignant brain tumors
Nobuyuki Kosaka et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2008)
Bevacizumab in recurrent malignant glioma
Lauren E. Abrey
Current Neurology and Neuroscience Reports (2008)
Bevacizumab - News from the fast lane?
Michael Weller et al.
NEURO-ONCOLOGY (2008)
Expression of VEGF and its receptor genes in intracranial schwannomas
Toshio Uesaka et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption
EA Neuwelt et al.
PEDIATRIC BLOOD & CANCER (2006)
Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas
Walter A. Hall et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Share Paper
